Original data asset
GLP-1 Access and Safety Tracker: Shortages, Compounding, Retatrutide
Track the difference between FDA-approved GLP-1 products, shortage context, compounded-product warnings, dosing-error alerts, and investigational retatrutide claims.
What the GLP-1 access and safety tracker shows
This tracker summarizes categories that are easy to confuse online: FDA-approved products, national shortage context, compounded-product warnings, and investigational retatrutide research.
It is not a pharmacy locator, provider list, prescribing guide, or treatment-selection tool. Medication choice, medication purchasing, provider choice, and compounded-product suitability require licensed clinical or pharmacy guidance.
What the GLP-1 tracker covers
Covered topics include FDA-approved GLP-1 and related incretin product labels, FDA shortage records, FDA compounding and unapproved-drug warnings, compounded semaglutide dosing-error alerts, and public retatrutide research status.
The page does not compare providers, rank products, estimate individual insurance coverage, quote cash prices, collect health information, or link to pharmacies.
Why FDA update dates matter
FDA shortage status, FDA compounding policy, enforcement actions, product labeling, and trial records can change. A statement that was accurate on one date may need to be rechecked when FDA or trial-registry records change.
If you are currently using, considering, or having trouble obtaining a GLP-1 medication, discuss the situation with a licensed clinician or pharmacist. Do not start, stop, switch, split, skip, restart, or change a medication dose based on a tracker row.
How to interpret GLP-1 shortage status
The FDA Drug Shortages Database is the controlling source for current national shortage status. Manufacturer availability statements, local pharmacy inventory, social media reports, clinic marketing, and patient anecdotes are not replacements for the FDA database.
National shortage status is not the same as local pharmacy inventory. A medication may be difficult to find locally even when national shortage status has changed, and local availability should be discussed with a pharmacist or prescriber.
How to interpret compounded GLP-1 warnings
Compounded drugs are not FDA-approved. FDA says consumers and health professionals rely on the FDA drug approval process for verification of safety, effectiveness, and quality, and that unnecessary compounded-drug use may expose patients to serious health risks.
FDA-approved products and compounded products are not the same category. Compounded GLP-1 products are not generic versions of brand medications, and compounded-product claims need current FDA sources.
How to interpret FDA GLP-1 safety updates
Safety updates are not treatment instructions. Topics include FDA warnings about unapproved GLP-1 drugs used for weight loss, compounded injectable semaglutide dosing errors, fraudulent products, improper shipping or storage, illegal online sales, warning letters, enforcement announcements, and label updates that affect patient safety education.
FDA reporting resources can be useful, but adverse-event management belongs with a licensed clinician, pharmacist, urgent care, emergency services, or poison control as appropriate for the situation.
Retatrutide investigational status boundary
Misleading retatrutide access claims are a safety risk because retatrutide is not FDA-approved.
Retatrutide is investigational and is not FDA-approved. Source-dated research status is different from clinical use, purchasing, compounding, prescribing, dosing, or provider access.
What to prepare before discussing GLP-1 care
Before a clinician or pharmacist conversation, identify the exact product, active ingredient, approval status, warning topics, and source questions that matter for this page.
Medication choice, dosing, pharmacy selection, and treatment planning require a licensed clinician who can evaluate medical history, contraindications, monitoring needs, other medications, pregnancy plans, and current product labeling.
Why GLP-1 treatment decisions require a clinician
Changing medication, managing symptoms, preparing injections, and interpreting a personal risk profile require clinician or pharmacist guidance.
Product labels, pharmacist counseling, and clinician follow-up remain the controlling sources for patient-specific decisions.
Why current labels and FDA updates matter
Approval status, compounding policy, shortage status, product labels, and trial status can change. Check the date on the source before relying on a high-change medical or regulatory claim.
Trial evidence applies to the studied population and endpoint. It is not a promise of an individual result.
How often status can change
FDA shortage status can change during active supply disruptions. FDA unapproved-drug and compounding information can change with enforcement or policy updates. Product labels can change when safety, indication, or labeling updates occur.
Retatrutide ClinicalTrials.gov records and Lilly sponsor-reported releases can change the research picture. Sponsor updates are not regulatory approval and should not be treated as prescribing information.
GLP-1 access and safety status as of 2026-05-27
| Category | What to know | Primary sources | Last verified |
|---|---|---|---|
| Semaglutide | FDA-approved semaglutide products have product-specific labels. Compounded semaglutide products are not FDA-approved. | DailyMed labels for Wegovy, Ozempic, and Rybelsus, plus FDA unapproved GLP-1 and dosing-error pages. | 2026-05-27 |
| Tirzepatide | FDA-approved tirzepatide products have product-specific labels. Compounded tirzepatide products are not FDA-approved. | DailyMed labels for Mounjaro and Zepbound, plus FDA unapproved GLP-1 and compounding-policy pages. | 2026-05-27 |
| Compounded GLP-1 products | Compounded GLP-1 products are not FDA-approved. FDA has warned about unapproved GLP-1 drugs, dosing errors, and counterfeit or fraudulent products. | FDA unapproved GLP-1 concerns, compounding Q&A, compounder-policy statements, and compounded semaglutide dosing-error alerts. | 2026-05-27 |
| Shortage and access context | National shortage status can differ from local pharmacy availability. Shortage status should not be turned into advice to switch products, seek compounded medication, or buy from a specific seller. | FDA Drug Shortages Database and FDA compounding-policy pages. | 2026-05-27 |
| Retatrutide / LY3437943 | Investigational only. It is not FDA-approved and is not prescription-access, compounding-access, or provider-access content. | ClinicalTrials.gov records, FDA unapproved GLP-1 warnings, and clearly labeled Lilly sponsor-reported releases. | 2026-05-27 |
GLP-1 Access and Safety Tracker: Shortages, Compounding, Retatrutide questions
Does the tracker show local pharmacy availability?
No. Local inventory can differ from national shortage or regulatory status and should be discussed with a pharmacist or prescriber.
Why is retatrutide included if it is not approved?
Misleading retatrutide access or compounding claims are a safety risk. Retatrutide remains investigational, not FDA-approved, and not prescription-access content.
GLP-1 Access and Safety Tracker: Shortages, Compounding, Retatrutide sources
- FDA concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration. Accessed 2026-05-27.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S. Food and Drug Administration. Accessed 2026-05-27.
- FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list, U.S. Food and Drug Administration. Accessed 2026-05-27.
- FDA drug shortages, U.S. Food and Drug Administration. Accessed 2026-05-27.
- FDA alert on dosing errors associated with compounded injectable semaglutide products, U.S. Food and Drug Administration. Accessed 2026-05-27.
- Compounding and the FDA: questions and answers, U.S. Food and Drug Administration. Accessed 2026-05-27.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight, ClinicalTrials.gov. Accessed 2026-05-27.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity, ClinicalTrials.gov. Accessed 2026-05-27.
- Lilly retatrutide Phase 3 obesity trial topline results, Eli Lilly and Company via PR Newswire. Accessed 2026-05-27.